<table id="table4" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4	Pharmacokinetic Parameters of Saquinavir at Steady-State After Administration of Different Regimens in HIV-1-Infected Subjects</caption>
<col align="left" span="1" valign="top" width="45%"></col>
<col align="center" span="1" valign="top" width="10%"></col>
<col align="center" span="1" valign="top" width="15%"></col>
<col align="center" span="1" valign="top" width="15%"></col>
<col align="center" span="1" valign="top" width="15%"></col>
<tbody>
<tr>
<th colspan="1">Dosing Regimen</th>
<th colspan="1">N</th>
<th colspan="1">AUC<sub>τ</sub>
<br/>(ng∙h/mL)</th>
<th colspan="1">AUC<sub>24h</sub>
<br/>(ng∙h/mL)</th>
<th colspan="1">C<sub>min</sub>
<br/>(ng/mL)</th>
</tr>
<tr>
<td>INVIRASE 600 mg tid (arithmetic mean, %CV)</td>
<td>10</td>
<td>866 (62)</td>
<td>2598</td>
<td>79</td>
</tr>
<tr>
<td>Saquinavir soft gel capsules 1200 mg tid (arithmetic mean)</td>
<td>31</td>
<td>7249</td>
<td>21747</td>
<td>216</td>
</tr>
<tr>
<td>INVIRASE 1000 mg bid + ritonavir 100 mg bid (geometric mean and 95% CI)</td>
<td>24</td>
<td>14607<br/>(10218-20882)</td>
<td>29214</td>
<td>371<br/>(245-561)</td>
</tr>
<tr>
<td>Saquinavir soft gel capsules 1000 mg bid + ritonavir 100 mg bid (geometric mean and 95% CI)</td>
<td>24</td>
<td>19085<br/>(13943-26124)</td>
<td>38170</td>
<td>433<br/>(301-622)</td>
</tr>
</tbody>
</table>